Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Mycobacterium Tuberculosis (M. tb)
100%
Texas
30%
United States
21%
Latent Tuberculosis Infection
20%
Atherosclerosis Treatment
18%
Air Force
18%
Prevention Study
18%
Lovastatin
16%
Tuberculosis Treatment
14%
Tuberculosis Patients
14%
Rifapentine
13%
Pulmonary Tuberculosis
13%
Directly Observed Therapy
11%
Pulmonary Impairment
11%
High-density Lipoprotein Cholesterol (HDL-C)
11%
95% Confidence Interval
10%
Tuberculin Skin Test
9%
Antiretroviral Therapy
9%
Tuberculosis Diagnosis
9%
CD8+ T Cells
9%
T Cells
9%
Placebo
9%
Major Coronary Events
8%
Low-density Lipoprotein Cholesterol (LDL-C)
8%
Primary Prevention
7%
HIV-infected Patients
7%
CD4+
7%
Relative Risk
7%
High Risk
7%
Adverse Events
7%
Statin Therapy
6%
Gemfibrozil
6%
HIV Infection
6%
Drug-resistant Tuberculosis (DR-TB)
6%
Once-weekly
6%
Odds Ratio
6%
Canada
5%
Treatment Completion
5%
AIDS/HIV
5%
Cholesterol
5%
Immunosuppressive Therapy
5%
Intracellular Pathogen
5%
Drug Resistance
5%
Acute Coronary Event
5%
Tolerability
5%
IS6110
5%
Randomized Clinical Trial
5%
Nursing and Health Professions
Tuberculosis
51%
Human Immunodeficiency Virus
14%
High Density Lipoprotein Cholesterol
8%
Isoniazid
8%
Diseases
7%
Coronary Artery Atherosclerosis
7%
Directly Observed Therapy
7%
Gemfibrozil
6%
Rifapentine
6%
Tuberculin Test
6%
Low Density Lipoprotein Cholesterol
6%
Latent Tuberculosis
5%
Cholesterol
5%
Education
5%
Lung Tuberculosis
5%
Immunosuppressive Treatment
5%
Lipoprotein
5%
Low Density Lipoprotein Cholesterol Level
5%
Medicine and Dentistry
Tuberculosis
48%
Human Immunodeficiency Virus
11%
Latent Tuberculosis
11%
Lung Tuberculosis
8%
Isoniazid
7%
Diseases
7%
Rifapentine
6%
Tuberculosis Treatment
6%
Education
6%
Immunosuppressive Treatment
5%
Directly Observed Therapy
5%
